{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:50:25Z","timestamp":1792763425642,"version":"4.5.0"},"reference-count":71,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,5,3]]},"DOI":"10.1080\/14656566.2025.2491508","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:23:57Z","timestamp":1744813437000},"page":"835-848","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence"],"prefix":"10.1080","volume":"26","author":[{"given":"Alberto","family":"Corsini","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano","place":["Milano, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00177"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.12.004"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35662"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000165979.46537.56"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-022-01219-4"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03373-w"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008441"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2022.12.004"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001092"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10214828"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10526-5"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.10.010"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200746"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00308-4"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2018-0336"},{"key":"e_1_3_5_18_1","unstructured":"European Medicines Agency. Alglucosidase alfa: summary of product characteristics. 2023 [cited 2023 Jun 13]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myozyme"},{"key":"e_1_3_5_19_1","unstructured":"Genzyme Corporation. Myozyme (alglucosidase alfa) injection for intravenous infusion. 2019 [cited 2023 Jun 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125141s222lbl.pdf"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.12.212"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000251268.41188.04"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12272"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.09.015"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909859"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5275-3"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100769"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc400365a"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198807000-00021"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53985-5"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.02.006"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.12.101"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.03.006"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.056119"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)83136-2"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.04.009"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.37"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2003.08.022"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.04.15"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8219-8"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004711"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.108119"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1746"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2804"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.57.070188.004033"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc1005416"},{"key":"e_1_3_5_46_1","unstructured":"Japanese Accepted Names (JAN) Name and Structure Database. Name and structure database. Avalglucosidase alfa (genetical recombination). JAN [cited 2023 Jun 7]. Available from: https:\/\/jpdb.nihs.go.jp\/jan\/DetailList_en.aspx?submit=all_alp+Search&keyword=Avalglucosidase+Alfa+%28Genetical+Recombination%29"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20050364"},{"key":"e_1_3_5_48_1","unstructured":"European Medicines Agency. Avalglucosidase alfa: summary of product characteristics. 2023 [cited 2023 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nexviadyme-epar-product-information_en.pdf"},{"key":"e_1_3_5_49_1","unstructured":"Genzyme Corporation. Nexviazyme (avalglucosidase alfa-ngpt) for injection for intravenous use. Genzyme corporation. 2023 [cited 2023 Jun 13]. Available from: https:\/\/products.sanofi.us\/nexviazyme\/nexviazyme.pdf"},{"key":"e_1_3_5_50_1","unstructured":"Amicus Therapeutics. Pombiliti (cipaglucosidase alfa-atga) for injection for intravenous use. 2023 [cited 2024 Feb 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761204s000lbl.pdf"},{"key":"e_1_3_5_51_1","unstructured":"European Medicines Agency. Cipaglucosidase alfa: summary of product characteristics. 2023 [cited 2023 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pombiliti-epar-product-information_en.pdf"},{"key":"e_1_3_5_52_1","unstructured":"European Medicines Agency. Pombiliti EPAR Public assessment report EMA 2022. Amicus Therapeutics Europe Limited; 2022 [cited 2023 Jun 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pombiliti"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125358"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00241-6"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00331-8"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.0552"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.01.566"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2021.11.050"},{"key":"e_1_3_5_59_1","unstructured":"Sanofi. Media update: new data demonstrate clinical safety benefit and durability of Nexviazyme\u00ae across a wide-range of Pompe disease patient groups. 2024 [cited 2025 Mar 27]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-02-05-23-00-00-2823915"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001593"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.53"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200309"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102092"},{"key":"e_1_3_5_64_1","unstructured":"European Patent Office. Highly potent acid alpha-glucosidase with enhanced carbohydrates: EP3201320A1. European Patent Office; 2023. [cited 2023 Jun 14]. Available from: https:\/\/patents.google.com\/patent\/EP3201320A1\/en"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1451512"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1540452"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10526-5"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020302"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf1691"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3470"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.024"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114683"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1221140"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2491508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:54:15Z","timestamp":1751547255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2491508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,5,3]]}},"alternative-id":["10.1080\/14656566.2025.2491508"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2491508","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}